Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Familial Hypocalciuric Hypercalcemia 2. Core disease mechanisms, molecular...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 20
• Snippets retrieved: 20

Relevant Papers

[1] Hypercalcemia. Pathophysiological aspects.

• Authors: I. Z̆ofková
• Year: 2016
• Venue: Physiological research
• URL: https://www.semanticscholar.org/paper/07e1255348bd1f4ff5acccd8fe008c6696a91ac6
• DOI: 10.33549/PHYSIOLRES.933059
• PMID: 26596315
• Citations: 29
• Summary: The metabolic pathways that contribute to maintain serum calcium concentration in narrow physiological range include the bone remodeling process, intestinal absorption and renal tubule resorption, which contribute to hyper- or hypocalcemia.
• Evidence snippets:
• Snippet 1 (score: 0.627) > The metabolic pathways that contribute to maintain serum calcium concentration in narrow physiological range include the bone remodeling process, intestinal absorption and renal tubule resorption. Dysbalance in these regulations may lead to hyper- or hypocalcemia. Hypercalcemia is a potentionally life-threatening and relatively common clinical problem, which is mostly associated with hyperparathyroidism and/or malignant diseases (90 %). Scarce causes of hypercalcemia involve renal failure, kidney transplantation, endocrinopathies, granulomatous diseases, and the long-term treatment with some pharmaceuticals (vitamin D, retinoic acid, lithium). Genetic causes of hypercalcemia involve familial hypocalciuric hypercalcemia associated with an inactivation mutation in the calcium sensing receptor gene and/or a mutation in the CYP24A1 gene. Furthermore, hypercalcemia accompanying primary hyperparathyroidism, which develops as part of multiple endocrine neoplasia (MEN1 and MEN2), is also genetically determined. In this review mechanisms of hypercalcemia are discussed. The objective of this article is a review of hypercalcemia obtained from a Medline bibliographic search.

[2] Applications of Metabolomics in Calcium Metabolism Disorders in Humans

• Authors: B. Podgórska, Marta Wielogórska-Partyka, J. Godzień, Julia Siemińska, M. Ciborowski et al.
• Year: 2022
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/c9aadd33d0b446d2859296c5b9d0ee0e69c43d59
• DOI: 10.3390/ijms231810407
• PMID: 36142318
• PMCID: 9499180
• Citations: 13
• Summary: The present review highlights the potential of metabolomics in identifying the biomarkers of some of the most common endocrine disorders, such as primary hyperparathyroidism (PHPT), secondary hyper parathyroidisms (SHPT), calcium deficiency, osteoporosis and vitamin D supplementation.
• Evidence snippets:
• Snippet 1 (score: 0.541) > It occurs either sporadically or as a familial, hereditary abnormality. The phenotypic diversity of PHPT clinical presentation may be due to the subclasses of parathyroid tumors with distinct molecular profiles [11]. Similarly to PHPT, familial hypocalciuric hypercalcemia (FHH) is a state that also leads to hypercalcemia and the elevation of PTH. Nevertheless, FHH is a rare inherited disorder with a mutation in the CaSRs. The opposite perturbation to hypercalcemia is hypocalcemia, which occurs in vitamin D deficiency and hypoparathyroidism due to irreversible parathyroidectomy, congenital disabilities or radiation damage [12,13]. > Changes in calcium levels can induce a wide spectrum of symptoms, including skeletal anomalies, nephrolithiasis and muscle spasms [1]. This frequently affects patients' quality of life and despite the great pressure on the development of novel methods of diagnosis and treatment, medical approaches to calcium metabolism disorders often pose a significant diagnostic challenge [14]. Functional analyses have become increasingly popular. Among these, metabolomics is the comprehensive analysis of the entire metabolome. This discipline enables the high-throughput analysis of metabolites from cells, tissues, organs and biofluids using modern analytical chemistry techniques [15]. Metabolomics is an important 'omic' approach. Metabolites, i.e., small molecules, are markers of various biological processes [1]. The growing popularity of metabolomics and the metabolites' capacity to serve as sources of novel potential biomarkers used in screening diseases and efficient therapies are observed in various medical disciplines. The metabolome can be explored through either the untargeted analysis of a wide set of unknown metabolites or the targeted quantification of pre-defined known metabolites [16]. > Metabolomics is still a relatively new field of science that links cellular phenotypes to their genotypes and delivers biochemical information associated with the regulation of specific gene transcripts [17]. Environmental factors may also induce metabolic changes.

[3] Single-cell profiling resolves gain- and loss-of-function mechanisms in CASR to advance mechanism-aware variant classification

• Authors: S. Padigepati, David A. Stafford, Y. Kobayashi, Christopher A. Tan, Joseph Kim et al.
• Year: 2026
• Venue: bioRxiv
• URL: https://www.semanticscholar.org/paper/1727abf71331fa7eaa5589bca437e34a0ad86551
• DOI: 10.64898/2026.09.26.754690
• Summary: The effectiveness of using molecular mechanism annotations with scRNA-seq to train models that distinguish molecular mechanisms of pathogenicity in CASR has immediate relevance for clinical variant classification and establishes a foundation for mechanism-guided clinical management in disorders with mechanism-dependent interventions.
• Evidence snippets:
• Snippet 1 (score: 0.528) > Here, we present a generalizable framework for predicting disease-specific mechanisms of pathogenicity in genes associated with multiple disorders. We combine single-cell RNA sequencing-based variant effect measurements with supervised machine learning, leveraging expert-curated sets of variants with known disease associations. We selected the calciumsensing receptor gene (CASR) as a model system because pathogenic variants in CASR are associated with two distinct clinical entities with opposing molecular etiologies: LOF variants cause familial hypocalciuric hypercalcemia type 1 (FHH1), 11 characterized by mild hypercalcemia with inappropriately low urinary calcium excretion, while GOF variants cause autosomal dominant hypocalcemia type 1 (ADH1), 12 marked by hypocalcemia with relative hypercalciuria. Using this system, we show that this integrated approach can not only identify pathogenic variants but also predict their specific disease mechanism, thereby enabling more precise clinical interpretation. This framework offers a path forward for resolving VUS in genes where multiple disease mechanisms complicate variant classification.

[4] A novel missense variant of the calcium-sensing receptor gene associated with familial hypocalciuric hypercalcemia

• Authors: Martina Laganà, Anna Maria Grieco, V. Guarnieri, M. Castori, R. Pracella et al.
• Year: 2025
• Venue: JBMR Plus
• URL: https://www.semanticscholar.org/paper/f3943b05c56b95ee09ad7c017ba39ab6f10e2be1
• DOI: 10.1093/jbmrpl/ziaf137
• PMID: 40978122
• PMCID: 12445840
• Summary: The present case expands the mutational spectrum of CASR and reinforces the clinical utility of multidisciplinary assessment for adults presenting with unexplained hypercalcemia.
• Evidence snippets:
• Snippet 1 (score: 0.517) > Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant inherited disorder caused by deleterious variants of three different genes. FHH type 1 (FHH1) is the most common genetic form and is associated with inactivating variants in the gene CA SR, which encodes for the calcium-sensing receptor (CaSR). CaSR is expressed on parathyroid cells, regulates calcium levels, and, consequently, PTH synthesis and release. 1 In a few cases, FHH derives from deleterious variants in the G-protein subunit α11 gene (GNA11), encoding the GNa-11 protein implicated in downstream CaSR signal transduction (FHH2), or in the adaptor-related protein complex 2 (AP2), sigma 1 subunit gene (AP2S1) that encodes the clathrin-associated AP2S1 protein involved in CaSR endocitosis (FHH3). 2 Loss-of-function (LoF) alterations in these genes increase the set-point for calcium sensing and consequently shift suppression of PTH secretion to a higher threshold of serum calcium concentration. Consequently, serum calcium exceeds the normal range, whereas serum PTH is inappropriately normal or mildly elevated, as the mechanism of negative feedback is compromised. Moreover, LoF variants lead to an increase in renal threshold for calcium tubular reabsorption, resulting in a lower renal calcium excretion than what is expected from the enhanced filtered load of calcium. 1,3,4 he differential diagnosis between FHH and other causes of hypercalcemia, mainly primary hyperparathyroidism (PHP), may be challenging, owing to variability in presentation and significant overlap, but it appears crucial for prognosis and correct treatment. > Familial hypocalciuric hypercalcemia remains largely underdiagnosed due to its frequently benign clinical course. Despite the rarity of the condition, clinicians should be advised to screen for FHH in patients with suggestive biochemical data (asymptomatic hypercalcemia and hypocalciuria) to prevent superf luous tests and unnecessary surgical treatment.

[5] Case Reports of Patients Diagnosed with Familial Hypocalciuric Hypercalcemia, A Disorder That Should be Kept in Mind in Hypercalcemia Cases

• Authors: A. Buluş, Y. Yaşartekin, A. Ceylan
• Year: 2022
• Venue: Trends in Pediatrics
• URL: https://www.semanticscholar.org/paper/05149d137a5977f214eef939b4da643ece818f33
• DOI: 10.4274/tp.2022.83007
• Summary: A family diagnosed with FHH is presented, having heterozygous CaSR mutations in three generations, and failure to diagnose FHH may result in unwarranted treatment or surgery for a false diagnosis of primary hyperparathyroidism, given the significant overlap of biochemical features.
• Evidence snippets:
• Snippet 1 (score: 0.515) > Y, Ceylan Case Reports of Patients Diagnosed with Familial Hypocalciuric Hypercalcemia, A Disorder that Should be Kept in Mind in Hypercalcemia Cases. Trends ABSTRACT Familial hypocalciuric hypercalcemia (FHH) causes hypercalcemia by three genetic mechanisms: Inactivating mutations in the calcium-sensing receptor ( CaSR ), G-protein subunit α11 or adapter-associated protein complex 2, sigma 1 subunit. In other cases, hypercalcemia causes significant morbidity and mortality, while FHH usually follows a benign course. Failure to diagnose FHH may result in unwarranted treatment or surgery for a false diagnosis of primary hyperparathyroidism, given the significant overlap of biochemical features. Patients carrying a heterozygous loss-of-function mutation in the CaSR gene are typically referred to as FHH-type 1 (FHH1). Although FHH1 causes lifelong hypercalcemia, it is usually benign and asymptomatic. FHH is the most common syndrome of CaSR gene mutation; it may sometimes be associated with a hypercalciuric tendency depending on the variant. Although hypercalcemia is a frequently encountered condition in our clinical practice, FHH is a clinic that we do not often think of. This paper presents a family diagnosed with FHH, having heterozygous CaSR mutations in three generations.

[6] Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies

• Authors: N. Makita, Junichiro Sato, Katsunori Manaka, Kimiko Akahane, Takahiro Ito et al.
• Year: 2022
• Venue: JCI Insight
• URL: https://www.semanticscholar.org/paper/394952935bd7c3b71b69dda4b7a8db2dc9a6c102
• DOI: 10.1172/jci.insight.156742
• PMID: 36099030
• PMCID: 9714797
• Citations: 5
• Summary: 3 patients with symptomatic AHH who shared characteristics with the 2 cases previously reported are described, and their observations may provide new insights into the phenotype and characteristics of AHH and the mechanisms by which the biased agonism of GPCRs operate.
• Evidence snippets:
• Snippet 1 (score: 0.498) > In the kidney, CaSR signaling activation in cells of the thick ascending loop of Henle results in hypercalciuria (23). Loss-of-function mutations of CaSR at 1 or both alleles inhibit CaSR signaling and cause increased PTH secretion, referred to as familial hypocalciuric hypercalcemia 1 (FHH1) and neonatal severe hyperparathyroidism (NSHPT), respectively (26,27). Also in the kidney, a CaSR signaling block in cells of the thick ascending loop of Henle causes hypocalciuria. > As an acquired disease analogous to ADH1, acquired hypoparathyroidism, including immune-checkpoint inhibitor-related hypoparathyroidism, has been reported to be caused by activating autoantibodies against CaSR (29)(30)(31)(32)(33)(34). Acquired hypocalciuric hypercalcemia (AHH), which is analogous to FHH1 or NSHPT, has been reported to be also caused by autoantibodies against CaSR (14,15,(35)(36)(37)(38). Depending on the reported AHH cases, autoantibodies work either as pure blocking entities (35) or in a biased manner (14,15). By investigating their mode of action, both the pathophysiological mechanisms underlying this heterologous disease from the perspective of the epitopes detected and possible effective treatments and the physiological mechanisms by which PTH secretion is regulated in the human body have been further elucidated (15). > In our present study, we report on 3 additional patients with AHH who were elderly men with no evidence of any other autoimmune disorders such as chronic thyroiditis, thus, differing from most autoimmune cases. This was also the case for the 2 patients with AHH we had previously described. These 3 individuals displayed symptomatic PTH-dependent hypercalcemia with hypocalciuria and were, thus, clinically suspected of having AHH. This diagnosis was subsequently confirmed using in vitro analysis. Their Ca levels spontaneously fluctuated from approximately normal to subfatally high ranges.

[7] A novel CaSR mutation presenting as a severe case of neonatal familial hypocalciuric hypercalcemia

• Authors: Ksenia N. Tonyushkina, S. O'Connor, N. Dunbar
• Year: 2012
• Venue: International Journal of Pediatric Endocrinology
• URL: https://www.semanticscholar.org/paper/da3271fb1d616d9c9f5ef0a89d45faecc566225d
• DOI: 10.1186/1687-9856-2012-13
• PMID: 22620673
• PMCID: 3465174
• Citations: 16
• Influential citations: 1
• Summary: This neonate with intrauterine fractures and demineralization, moderate hypercalcemia and hyperparathyroidism was found to have a novel inactivating missense mutation of the CaSR not detected in her mother.
• Evidence snippets:
• Snippet 1 (score: 0.485) > Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant disorder characterized by modestly elevated serum calcium (Ca), inappropriately high parathyroid hormone (PTH) levels and low urinary Ca excretion [1]. FHH is caused by inactivating mutations of the gene encoding the Calcium-Sensing Receptor (CaSR), a seven transmembrane G-protein-coupled receptor. The CaSR is expressed primarily in parathyroid chief cells and renal tubular cells and activates an intracellular signaling cascade to maintain serum calcium levels within a narrow range. The gene for the CaSR is located on chromosome 3q13.3-21 and encodes for a 1078 amino acid sequence. Normally, elevated levels of serum calcium activate the CaSR which then inhibits both the secretion of PTH in the parathyroid glands and the reabsorption of Ca 2+ and Mg 2+ in the renal tubules. Therefore an inactivating mutation of the CaSR leads to an elevated set point for serum Ca with the consequence of having both inappropriate secretion of PTH and renal reabsorption of Ca 2+ [2]. > The clinical impact of these mutations, at least 250 of which have been reported, is highly variable and ranges from totally asymptomatic to fatal. In the neonatal period, homozygous inactivating mutations result in neonatal severe hyperparathyroidism (NSHPT) with severe symptomatic hypercalcemia, undermineralized bones, rib cage deformity, and long-bone and rib fractures [3]. This condition requires aggressive medical management often including emergent parathyroidectomy and can be fatal. Neonatal heterozygous inactivating mutations are usually associated with modest hypercalcemia and hyperparathyroidism with mild or absent bone disease which gradually evolves to a more benign FHH phenotype [4][5][6][7]. Lastly, heterozygous FHH can go wholly unrecognized for years until elevated serum calcium is noted [8].

[8] Clinical, Biochemical, and Genetic Profile of an Indian Kindred with Type 1 Familial Hypocalciuric Hypercalcemia

• Authors: S. Alam, Alpesh Goyal, N. Tandon
• Year: 2021
• Venue: Indian Journal of Endocrinology and Metabolism
• URL: https://www.semanticscholar.org/paper/ae6b8b00d7320660b7761d97cefa0976e59938de
• DOI: 10.4103/ijem.ijem_349_21
• PMID: 35300448
• PMCID: 8923312
• Citations: 2
• Summary: An Indian kindred with genetically confirmed type 1 FHH where the presentation in the index case was delayed till the age of 48 years, and confounded by secondary hyperparathyroidism related to vitamin D deficiency is described.
• Evidence snippets:
• Snippet 1 (score: 0.475) > Sir, Familial hypocalciuric hypercalcemia (FHH) is a rare genetic disorder with autosomal dominant inheritance and high penetrance that manifests with mild parathyroid hormone (PTH)-dependent hypercalcemia and hypocalciuria. [1,2] he disorder results from an inherited defect in calcium sensing mechanism at the level of parathyroid gland and the thick ascending limb of loop of Henle of kidney. [3] FHH is genetically heterogenous and three subtypes have been described, namely, FHH1, FHH2, and FHH3, related to inactivating mutations in the genes encoding calcium sensing receptor (CaSR), G-protein subunit alpha-11 (GNA11), and adaptor-related protein complex 2 sigma 1 subunit (AP2S1) proteins, respectively. [3] Most patients with FHH are asymptomatic. [4] The disorder runs a benign course in most patients; parathyroidectomy is neither required, nor it is curative. [5] Symptoms of neonatal hypocalcemia have been described in unaffected children of women affected with this rare disorder. [6] Here, we describe an Indian kindred with genetically confirmed type 1 FHH where the presentation in the index case was delayed till the age of 48 years, and confounded by secondary hyperparathyroidism related to vitamin D deficiency. > A 48-year-old female initially presented to an orthopedic specialist with complaints of generalized body ache for the past 2 years. Her initial work-up including complete blood count, liver and kidney function tests was unremarkable. She had mild hypercalcemia (serum calcium: 10.8 mg/ dL, N: 8.5-10.5 mg/dL), mild hypophosphatemia (serum phosphate: 2.4 mg/dL, N: 2.5-4.5 mg/dL), raised serum PTH (164.7 pg/mL, N: 15-65 pg/mL), and low serum 25-hydroxyvitamin D levels (6.8 ng/mL, N: 20-50 ng/ mL) [Table 1].

[9] Familial Syndromes of Primary Hyperparathyroidism

• Authors: W. Simonds
• Year: 2020
• Venue: Calcium Disorders, Hypercalcemia and Hypocalcemia - Recent Advances, New Perspectives and Treatments [Working Title]
• URL: https://www.semanticscholar.org/paper/b6e10049c4507f0eb117c3721ebc63ed57bf4d79
• DOI: 10.5772/intechopen.93036
• Citations: 2
• Summary: Future approaches for the discovery of novel genes pertinent to parathyroid tumor development are the analysis of acquired genetic alterations in DNA isolated from parathyoid tumors and the investigation of familial HPT in kindreds lacking germline mutation in the known genes predisposing to HPT.
• Evidence snippets:
• Snippet 1 (score: 0.468) > PTH secretion from cells of the parathyroid glands is finely regulated in response to changes in the ambient ionized calcium level in order to maintain the circulating calcium concentration within a defined physiologic range. The G protein-coupled CASR is a critical regulator of PTH secretion and is located on the plasma membrane of chief cells in the parathyroid glands [10,11]. In a classic endocrine negative feedback loop, the active form of cholecalciferol, 1,25-dihydroxyvitamin D, whose synthesis is stimulated by PTH acting on proximal renal tubular cells, inhibits PTH biosynthesis and release from parathyroid cells [12][13][14][15]. The simultaneous demonstration of elevated serum calcium with an inappropriately normal or elevated PTH is a typical clinical definition of HPT [16]. The vast majority of parathyroid tumors are adenomas (i.e. benign tumors), with parathyroid cancer accounting for less than 1% of HPT in most series. > Most cases of HPT are sporadic with inherited forms of HPT representing only 2-5% of cases. As illustrated in Table 1, research into the molecular pathophysiology of this small subcategory of cases has notwithstanding yielded important understanding with respect to the genes and pathways that promote parathyroid tumorigenesis. Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), the hyperparathyroidism-jaw tumor syndrome (HPT-JT), and familial isolated hyperparathyroidism (FIHP) are the most common inherited disorders associated with . Familial hypocalciuric hypercalcemia (FHH) is a related and largely benign autosomal dominant condition characterized by lifelong asymptomatic hypercalcemia. Often mis-diagnosed as HPT, in FHH the PTH-dependent hypercalcemia does not correct with partial or even subtotal parathyroidectomy [22]. The relevance of these inherited disorders to the underlying molecular pathogenetic alterations in parathyroid tumorigenesis will be discussed in more detail below.

[10] Exploring global calcimimetics research trends: a systematic and thematic review of Web of Science and Scopus databases from 1997 to 2024

• Authors: R. Abdelrahman, T. Musa, C. L. Mgbechidinma, E. O. Ahmed
• Year: 2025
• Venue: Frontiers in Nephrology
• URL: https://www.semanticscholar.org/paper/8d22281d01f2b59e9c3d14da3c191d404588a7d5
• DOI: 10.3389/fneph.2025.1617466
• PMID: 40881674
• PMCID: 12380556
• Citations: 1
• Summary: While the thematic map highlighted robust research on the pathophysiology of CKD-MBD, critical clinical outcomes remain underexplored and future trials should highlight these gaps, particularly in high-risk subgroups such as diabetic patients with CKD.
• Evidence snippets:
• Snippet 1 (score: 0.467) > The thematic map of the authors' keywords revealed four distinct clusters of research themes related to calcium metabolism and kidney disease, indicating interdisciplinary connections. The key observations reported cluster "chronic kidney disease (CKD) & mineral disorders" in basic and motor themes, followed by "calcium homeostasis & genetic disorders" in niche themes, which included highlights of the genetic and molecular mechanisms of calcium regulation [familial hypocalciuric hypercalcemia (FHH) as a niche area]. The "hypercalcemia" cluster linked hypercalcemic states to bone pathologies, located in the emerging and basic themes. "Chronic kidney disease" was the most dominant research, and "vascular calcification" was a critical sub-theme (Figure 7A). > The thematic KeyWords Plus analysis in Figure 7B identified three key domains, including pharmacological targets (CaSR and cinacalcet) reported in niche themes and central CKD-MBD pathway (HD, vascular calcification, and vitamin D) cases as reported in emerging/declining themes. The small association between "diabetes" and "mineral metabolism" (despite shared CKD complications) suggests a critical research gap. > Figure 7C illustrates a thematic clustering process that used abstract words, likely from a biomedical or pharmacological study, focusing on keywords related to calcium sensing and receptor modulation. The structure suggests an emerging thematic analysis, where the dominant topics were grouped hierarchically or by relevance. These findings suggest that "calcium-sensing receptors" and "effects calcimimetic" are major research subjects.

[11] Familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a case report of an unusual association and literature review

• Authors: Emre Inan, Ezgi Ulaş, Hatice Özışık, Gokcen Ünal Kocabaş, Mehmet Yiğit et al.
• Year: 2025
• Venue: The Egyptian Journal of Internal Medicine
• URL: https://www.semanticscholar.org/paper/e048f73bdcb9b11550ae539361d65c59f968f0db
• DOI: 10.1186/s43162-025-00564-0
• Summary: Patients may still exhibit mild to moderate hypercalcemia following surgery, thus more invasive procedures should be avoided; failure of parathyroid exploration should not be assumed.
• Evidence snippets:
• Snippet 1 (score: 0.466) > Familial Hypocalciuric Hypercalcemia (FHH) represents a group of rare genetic diseases caused by inactivating mutation in the calcium-sensing receptor (CaSR) gene or its associated proteins. It is marked by persistent hypercalcemia, typically asymptomatic, improperly diminished urine calcium excretion, and resistance Familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a case report of an unusual association and literature review Emre İnan 1* , Ezgi Ulaş 1 , Hatice Özışık 1 , Gökçen Ünal Kocabaş 1 , Mehmet Yiğit 1 , Ayça Aykut 1 , Asude Durmaz 1 , Yeşim Ertan 1 , Murat Özdemir 1 , Mehmet Erdoğan 1 and Banu Pınar Şarer Yürekli 1 genotype-phenotype relationships. To date, over 200 CASR mutations have been identified [3]. Mutations affecting the chromosome region 19p13.3 are categorized as FHH2 when caused by loss of function mutations in the GNA11 gene, which encodes the G-protein subunit α11 [4]. Similarly, they are classified as FHH3 when resulting from loss of function mutations in the AP2S1 gene, responsible for encoding the sigma 1 subunit of the adaptor-related protein complex 2 (AP2σ) [5]. > Primary hyperparathyroidism (PHPT) frequently leads to hypercalcemia in adults, often requiring surgical intervention, particularly when end-organ damage is present or when the patient is young. The risks of prolonged monitoring are considered too uncertain to avoid definitive treatment [6]. Most patients with PHPT are diagnosed not due to symptoms indicative of PHPT but rather through routine clinical practice, as serum calcium is commonly included in standard basic metabolic panel assessments [3]. In 80-90% of cases, PHPT is attributed to the presence of a solitary parathyroid adenoma. About 10-15% of cases are due to four-gland hyperplasia, 5% are due to multiple adenomas, and less than 1% are caused by parathyroid malignancies [7].

[12] Biased antibodies and beyond: a new era in the diagnosis of PTH-dependent hypercalcemia

• Authors: Noriko Makita, Katsunori Manaka, Maho Taguchi, Hirofumi Horikoshi, Junichiro Sato et al.
• Year: 2025
• Venue: Endocrine Journal
• URL: https://www.semanticscholar.org/paper/558d736d9ff595c82490d7b7bf187064e007b01b
• DOI: 10.1507/endocrj.EJ25-0051
• PMID: 40335290
• PMCID: 12436076
• Citations: 1
• Summary: A novel diagnostic guide for PTH-dependent hypercalcemia is proposed, anticipating that this guide will help identify previously undiagnosed AHH cases in routine practice, enabling timely and effective management of this rare condition.
• Evidence snippets:
• Snippet 1 (score: 0.465) > Hypercalcemia, a common electrolyte imbalance, requires accurate differential diagnosis to guide appropriate management. PTH-dependent hypercalcemia, predominantly caused by primary hyperparathyroidism (PHPT) and rarely by familial hypocalciuric hypercalcemia (FHH)—mainly due to heterozygous loss-of-function mutations in the CASR gene encoding the calcium-sensing receptor (CaSR)—now includes acquired hypocalciuric hypercalcemia (AHH) as an emerging disease entity. Initially identified as analogous to FHH, AHH was characterized by blocking antibodies targeting the CaSR. However, our research has identified unique autoantibodies, termed biased antibodies, that paradoxically regulate signaling by enhancing Gq activity while suppressing Gi activity. Investigating their mechanisms has not only provided insights into specific treatments for AHH but also suggested novel activation mechanisms and binding sites of the CaSR, offering a fresh perspective on the regulation of PTH secretion. In clinical practice, recognizing AHH is crucial. A key diagnostic feature is fluctuating serum calcium levels, making a wait-and-see approach viable for mild hypercalcemia. Conversely, hypercalcemic crises necessitate immediate diagnostic and therapeutic interventions. The most important diagnostic clue to differentiate AHH from PHPT is hypermagnesemia. Additionally, AHH is less likely to involve AVP resistance (i.e., nephrogenic diabetes insipidus) and acute kidney injury (AKI), owing to preserved medullary hyperosmolarity and minimal interference with AVP signaling. Finally, a relatively low PTH level serves as another distinguishing feature. Based on these observations, we propose a novel diagnostic guide for PTH-dependent hypercalcemia. We anticipate that this guide will help identify previously undiagnosed AHH cases in routine practice, enabling timely and effective management of this rare condition.

[13] Case Report: Severe Neonatal Course in Paternally Derived Familial Hypocalciuric Hypercalcemia

• Authors: Jakob Höppner, Sabrina Lais, C. Roll, A. Wegener-Panzer, D. Wieczorek et al.
• Year: 2021
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/84b1859574413f8e62244408e65f6b7b256f9523
• DOI: 10.3389/fendo.2021.700612
• PMID: 34659108
• PMCID: 8518617
• Citations: 5
• Summary: Familial hypocalciuric hypercalcemia is a mostly benign condition, but transient neonatal hyperparathyroidism may occur in affected neonates if the mutation is paternally inherited, and the condition can be treated successfully with cinacalcet.
• Evidence snippets:
• Snippet 1 (score: 0.458) > Loss-of-function mutations in the calcium-sensing and signaling pathway cause a spectrum of calcium-hyposensitivity-disorders with elevated PTH secretion (1). The resulting disorders can be summarized by inappropriately high PTH concentration despite elevated serum calcium levels. > Familial hypocalciuric hypercalcemia (FHH) comprises a genetically heterogenic group (2): FHH1 [OMIM #145980] is caused by heterozygous inactivating mutations in the calciumsensing receptor (CaSR) gene (3). FHH2 and 3 are caused by mutations in genes encoding for proteins involved in calcium signal transduction (4)(5)(6). The CaSR is a member of the subfamily of G protein-coupled transmembrane receptors and is expressed in parathyroid chief cells and the renal tubulus (7). FHH typically presents with the biochemical triad: life-long, non-symptomatic, non-progressive hypercalcemia, normal or slightly elevated serum PTH levels and hypocalciuria (8). Thus, FHH is thought to be a mostly benign condition, with no definite association to adverse outcomes (8). Accordingly, the vast majority of patients with FHH do not require medical or surgical treatment (2,9) and counseling of affected individuals aims to avoid future misdiagnosis and unnecessary parathyroidectomies (9,10). > In contrast to the clinically benign course of FHH1, neonatal severe primary hyperparathyroidism (NSHPT) [OMIM #239200] is a severe rare disease associated with a high mortality and is usually caused by homozygous inactivating mutations in the CaSR gene (8,11). Infants with NSHPT develop severe and symptomatic hypercalcemia with muscular hypotonia, respiratory distress, fractures, intestinal dysmotility, and failure to thrive in the early days of life (12)(13)(14).

[14] Integrated Whole-Exome and Transcriptome Sequencing of Sporadic Parathyroid Adenoma

• Authors: Ya Hu, Xiang Zhang, O. Wang, M. Cui, Xiaobin Li et al.
• Year: 2021
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/9df21dbc09335b81fbc6861045797d78ba81bf29
• DOI: 10.3389/fendo.2021.631680
• PMID: 34054720
• PMCID: 8163014
• Citations: 16
• Summary: According to the RNA-seq data clustering analysis, cyclin D1, β-catenin, VDR, CASR and GCM2 may be important factors contributing to the PA gene expression profile.
• Evidence snippets:
• Snippet 1 (score: 0.450) > Primary hyperparathyroidism (pHPT) is a common endocrine disorder with an incidence of approximately 66 and 25 per 100000 person-years among women and men, respectively (1). It was reported that the prevalence of pHPT was as high as 2.1% in postmenopausal women (2). The parathyroid tumor tissue secretes excessive parathyroid hormone, which results in hypercalcemia and related complications, such as osteoporosis, bone fracture, urolithiasis and renal failure. Parathyroid adenoma (PA) accounts for approximately 85% of pHPT. The genetic mechanisms of PA are not fully known, even though tremendous efforts have been made in previous studies. In PA with a hereditary background, the most wellknown driver gene of PA was multiple endocrine neoplasia type 1 (MEN1). Other possible driver genes for hereditary pHPT include RET in MEN-2, CDKN1B in MEN-4, CDC73 in hyperparathyroidism-jaw tumor syndrome, GCM2 in familial isolated pHPT, CASR in familial hypocalciuric hypercalcemia type 1, GNA11 in familial hypocalciuric hypercalcemia type 2, and AP2S1 in familial hypocalciuric hypercalcemia type 3. For sporadic PA, somatic mutation of MEN1 was identified in approximately 35% of cases (3). Mutation of CCND1 or overexpression of cyclin D1 was found in 30% of sporadic PA cases. Other genes, such as CASR, EZH2, CDKI, and CTNNB1, may also contribute to the tumorigenesis of PA. However, the driver genes could still not be identified in a substantial proportion of sporadic PA. > Several studies have explored the molecular mechanism of PA with next-generation sequencing (NGS) technologies, such as whole-exome sequencing (WES) or transcriptome sequencing (RNA-seq). In 2018, Wei et al. (4) used WES to explore genetic abnormalities in 20 specimens of PAs.

[15] Genetics of Hyperparathyroidism Including Parathyroid Cancer

• Authors: W. Simonds
• Year: 2017
• Venue: Endocrinology and metabolism clinics of North America
• URL: https://www.semanticscholar.org/paper/8d3c8f863c00b638106b63e7a446fb3a39c7e346
• DOI: 10.1016/j.ecl.2017.01.006
• PMID: 28476229
• PMCID: 5424626
• Citations: 26
• Influential citations: 5
• Summary: Primary hyperparathyroidism is a metabolic disease caused by the excessive secretion of parathyroid hormone from one or more neoplastic parathyroid glands that can be associated with a familial syndrome.
• Evidence snippets:
• Snippet 1 (score: 0.450) > Maintenance of the serum calcium concentration within a relatively narrow physiologic range is achieved by regulation of parathyroid hormone (PTH) secretion from parathyroid cells in response to changes in the circulating ionized calcium level. The G protein-coupled CaSR located on the surface membrane of the parathyroid chief cells negatively regulates the secretion of PTH. 2,3 In clinical medicine, HPT is typically defined by the conjunction of elevated serum ionized calcium with inappropriately elevated PTH. 1 Most parathyroid tumors are benign adenomas. Parathyroid carcinoma is a rare cause of HPT seen in less than 1% of cases. > Approximately 2 to 5 % of cases of HPT are associated with familial disease. Study of this small subset has nevertheless provided great insight into the genetic changes and molecular pathways that promote parathyroid neoplasia ( Table 1). The most common genetic disorders associated with HPT are MEN1, multiple endocrine neoplasia type 2A (MEN2A), HPT-JT, and familial isolated hyperparathyroidism (FIHP). [4][5][6][7] Familial hypocalciuric hypercalcemia (FHH) is a related, genetically heterogeneous, largely benign condition of PTH-dependent hypercalcemia often mimicking HPT that does not correct with partial or subtotal parathyroidectomy (PTX). 8 These genetic disorders and their relation to the underlying molecular and genetic alterations relevant to parathyroid neoplasia will be discussed in detail below.

[16] Disorders of the Calcium Sensing Signaling Pathway: From Familial Hypocalciuric Hypercalcemia (FHH) to Life Threatening Conditions in Infancy

• Authors: Jakob Höppner, Kathrin Sinningen, A. Raimann, B. Obermayer-Pietsch, C. Grasemann
• Year: 2022
• Venue: Journal of Clinical Medicine
• URL: https://www.semanticscholar.org/paper/12f8f3ef678598e485ff1062c8faa0877eacb3ee
• DOI: 10.3390/jcm11092595
• PMID: 35566721
• PMCID: 9100033
• Citations: 18
• Influential citations: 1
• Summary: This review focuses on the genetic and pathophysiological framework that leads to the severe neonatal form of familial hypocalciuric hypercalcemia, gives recommendations for counselling and summarizes treatment options.
• Evidence snippets:
• Snippet 1 (score: 0.449) > Loss-of-function (LOF) mutations in the calcium-sensing pathway may cause various calcium-hyposensitivity-diseases which are characterized by elevated serum calcium levels. Pathophysiologically, this is based on a shift of the 'set point' of the calcium concentration at which PTH secretion is half-maximal [1]. The resulting disorders share a constellation of inappropriately high PTH concentrations despite elevated serum calcium levels and are categorized into three groups based on genetic origin, time of onset and severity of clinical symptoms, namely familial hypocalciuric hypercalcemia (FHH), neonatal severe primary hyperparathyroidism (NSHPT), and neonatal hyperparathyroidism (NHPT) [2][3][4]. > FHH comprises a genetically heterogeneous group [5]: FHH1 [OMIM #145980] is usually caused by heterozygous inactivating mutations in the calcium sensing receptor gene (CaSR) and accounts for about 65% of all FHH cases [3]. Mutations in other genes encoding for proteins with a role in calcium signaling (GNA11 and AP2S1) cause FHH2 and 3 [6][7][8]. > The aims of this review are to present the pathophysiology of calcium-sensing receptor signaling disorders with a focus on intra-uterine calcium homeostasis and the differing clinical outcomes in neonates.

[17] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, P. A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 39
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.446) > However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[18] Research progress on pathogenic genes of dilated cardiomyopathy

• Authors: Xiao Zhang, Xin-Yue Zhang, Yun-Ru Chen, Na Huan, Chenglong Wang et al.
• Year: 2026
• Venue: iScience
• URL: https://www.semanticscholar.org/paper/44e063ee7afd11e0d1d30ad4fe9080e16b2c1bf4
• DOI: 10.1016/j.isci.2026.115511
• PMID: 42058912
• PMCID: 13122708
• Citations: 1
• Summary: Summary Dilated cardiomyopathy (DCM) is a primary myocardial disorder characterized by progressive ventricular dilatation and impaired myocardial systolic contractility, and it represents the most common form of cardiomyopathy globally. DCM drives a substantial worldwide disease burden, thus presenting a formidable and persistent challenge to global public health systems. The pathogenesis of DCM is marked by extreme etiological heterogeneity: 30%–50% of cases have a familial origin, with gene...
• Evidence snippets:
• Snippet 1 (score: 0.446) > This paper focuses on exploring the mechanisms of familial hereditary DCM. In addition to familial hereditary DCM, acquired DCM also exists in clinical practice. This type of DCM is primarily caused by environmental factors acting on a potential genetic predisposition, such as infectious DCM, which accounts for approximately 95% of acquired DCM cases. 204 It is important to emphasize that acquired DCM differs significantly from familial hereditary DCM. This section will exclusively address familial hereditary DCM. DCM disease-causing genes exhibit high heterogeneity, with significant variations in the proportion of patients affected by different genes. This results in ''single-gene mutation-targeted drugs'' covering only a very small fraction of patients. Even for TTN, the most prevalent gene, such drugs cover only 25% of end-stage/familial DCM patients. The proportion of patients affected by other genes is even lower, meaning ''single-gene drugs'' inherently face the problem of a ''narrow target population'' from the outset. This strict ''gene-mechanism-drug'' correspondence limits each drug class to serving only a tiny patient subgroup, making large-scale clinical application difficult. Furthermore, merely improving downstream symptoms cannot halt the core pathological processes driving disease progression. Therefore, we can shift our research focus upstream to explore the common pathological environment that leads to mutations in relevant disease-causing genes, the likelihood of staged gene mutations, or improve the internal environment to activate the body's gene repair mechanisms for treating DCM. Therefore, future therapies should not only target single-gene treatments but also explore how to improve the shared pathological environment. By reversing the ''soil'' in which gene mutations take effect, we can achieve broad-spectrum intervention for polygenic DCM.

[19] Control of PTH secretion by the TRPC1 ion channel

• Authors: Marta Onopiuk, B. Eby, V. Nesin, Peter Ngo, M. Lerner et al.
• Year: 2020
• Venue: JCI Insight
• URL: https://www.semanticscholar.org/paper/8b25128bce63ef887aa258a7432dedb4bed01e37
• DOI: 10.1172/jci.insight.132496
• PMID: 32213715
• PMCID: 7205425
• Citations: 11
• Summary: Mice lacking the transient receptor potential canonical channel 1 (TRPC1) develop chronic hypercalcemia, hypocalciuria, and elevated PTH levels, mimicking human FHH, and TRPC1-mediated Ca2+ signaling is identified as an essential component of the cellular apparatus controlling PTH secretion in the PTG downstream of CaSR.
• Evidence snippets:
• Snippet 1 (score: 0.442) > Familial hypocalciuric hypercalcemia (FHH) is a genetic condition associated with hypocalciuria, hypercalcemia, and, in some cases, inappropriately high levels of circulating parathyroid hormone (PTH). FHH is associated with inactivating mutations in the gene encoding the Ca2+-sensing receptor (CaSR), a GPCR, and GNA11 encoding G protein subunit α 11 (Gα11), implicating defective GPCR signaling as the root pathophysiology for FHH. However, the downstream mechanism by which CaSR activation inhibits PTH production/secretion is incompletely understood. Here, we show that mice lacking the transient receptor potential canonical channel 1 (TRPC1) develop chronic hypercalcemia, hypocalciuria, and elevated PTH levels, mimicking human FHH. Ex vivo and in vitro studies revealed that TRPC1 serves a necessary and sufficient mediator to suppress PTH secretion from parathyroid glands (PTGs) downstream of CaSR in response to high extracellular Ca2+ concentration. Gα11 physically interacted with both the N- and C-termini of TRPC1 and enhanced CaSR-induced TRPC1 activity in transfected cells. These data identify TRPC1-mediated Ca2+ signaling as an essential component of the cellular apparatus controlling PTH secretion in the PTG downstream of CaSR.

[20] Cinacalcet reverses short QT interval in Familial Hypocalciuric Hypercalcemia type 1

• Authors: T. Cuny, P. Romanet, M. Goldsworthy, Carole Guerin, Marie Wilkin et al.
• Year: 2023
• Venue: The Journal of clinical endocrinology and metabolism
• URL: https://www.semanticscholar.org/paper/e3e574e1855420fdea1c760d2bc6d1a8c5063d69
• DOI: 10.1210/clinem/dgad494
• PMID: 37602721
• PMCID: 7615553
• Citations: 3
• Summary: The results indicate that FHH-1 patients should be assessed for a short QT interval, and a cinacalcet test used to select patients who are likely to benefit from this treatment.
• Evidence snippets:
• Snippet 1 (score: 0.441) > Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant genetic disease mainly caused by germline calcium-sensing receptor (CASR) inactivating mutations (also called FHH-1)(1). More rarely FHH can be related to AP2S1 or GNA11 inactivating mutation, both genes encoding for proteins involved downstream of CASR activation (2,3). > FHH is usually characterized by mild elevation of calcemia with inappropriate or normal plasma parathyroid hormone (PTH) and, eventually, very low 24-hour urinary calcium excretion, best expressed by a urine calcium-to-creatinine clearance ratio (CCCR) <0.01 (3). Parathyroid thyroid imaging, if done, can be negative, a finding that together with hypocalciuria should raise the suspicion of FHH and argued against parathyroidectomy (4). > Hypercalcemia can be complicated by cardiac arrhythmias, as a consequence of a short QT interval (5). To date there is no data reporting the occurrence of possible cardiac arrhythmias in FHH-1 patients, possibly linked to the mild biochemical phenotype usually observed in this context. > Cinacalcet, a positive allosteric modulator of CaSR, can decrease PTH secretion (6) and was successfully used for FHH with a more severe hypercalcemia (7,8), however its benefits in mild presentation of FHH is counterbalanced by possible side effects (hypocalcemia, nausea, vomiting) and cost burden (9,10). In certain circumstances, the use of cinacalcet can be discussed on an individual basis at a multidisciplinary team meeting to ensure proper indication and follow-up. This can be the case in patients with short QT interval, a finding that could predispose to sudden cardiac death (11). Here, we present three family members with FHH-1 and a severe short QT interval who were potential candidates for cinacalcet therapy after demonstrating their sensitivity to the compound via a cinacalcet test.

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Reference Validation

Checked with linkml-reference-validator 0.3.0.

All extracted references resolved successfully.

Term Validation

No ontology term identifiers were found in this report.

Familial Hypocalciuric Hypercalcemia Type 2 (FHH2): Comprehensive Disease Characterization

Disease: Familial Hypocalciuric Hypercalcemia 2 (FHH2) MONDO ID: MONDO:0007792 · OMIM: #145981 · Category: Mendelian (autosomal dominant) Causal gene: GNA11 (Gα11), chromosome 19p13.3

Summary

Familial Hypocalciuric Hypercalcemia type 2 (FHH2) is a rare, autosomal dominant, and generally benign inherited disorder of calcium homeostasis. It is caused by heterozygous loss-of-function germline mutations in GNA11, the gene on chromosome 19p13.3 that encodes Gα11 (G-protein subunit α-11) — the heterotrimeric G-protein that couples the calcium-sensing receptor (CaSR) to downstream phospholipase C-β (PLCβ) signaling in parathyroid chief cells and renal tubular cells. Because Gα11 is the intracellular relay for the CaSR, loss-of-function variants reduce the potency of extracellular calcium at the receptor, producing a rightward shift (higher EC50) in the calcium concentration–response curve. The physiological consequence is an upward shift in the "set-point" for calcium: the parathyroid glands and kidney behave as though serum calcium were lower than it actually is, so PTH secretion is not suppressed and renal tubular calcium reabsorption persists. Clinically this yields lifelong mild hypercalcemia, inappropriately normal or high-normal PTH, and relative hypocalciuria (calcium-to-creatinine clearance ratio, CCCR, typically ≤0.01).

FHH2 is the rarest of the three recognized FHH subtypes (FHH1 = CASR, ~65% of cases; FHH3 = AP2S1; FHH2 = GNA11). As of 2026, only approximately eight FHH2 kindreds have been reported worldwide. The condition is usually asymptomatic with normal life expectancy, and its principal clinical importance lies in distinguishing it from primary hyperparathyroidism (PHPT) so that patients are not subjected to inappropriate and unhelpful parathyroidectomy. When treatment of significant hypercalcemia is warranted, the calcimimetic cinacalcet — an allosteric CaSR activator — corrects the biochemical abnormality both in a validated mouse model and in human patients.

GNA11 behaves as a striking bidirectional allelic series: germline loss-of-function → FHH2 (hypercalcemia); germline gain-of-function → autosomal dominant hypocalcemia type 2 (ADH2) (hypocalcemia); and somatic activating mutations → uveal melanoma via constitutive MAPK signaling. A newly recognized (2026) manifestation links GNA11 truncating/deletion variants to abnormal enamel mineralization, the first report connecting hypomineralized enamel to a hypercalcemic (rather than hypocalcemic) condition. Perinatally, maternal FHH can cause transient neonatal calcium disturbances in offspring depending on which genotype the newborn inherits.

Section 1 — Disease Information

Overview. FHH2 is a Mendelian, autosomal dominant disorder of systemic calcium homeostasis characterized by mild, lifelong, non-progressive hypercalcemia accompanied by inappropriately normal-to-mildly-elevated parathyroid hormone (PTH) and low urinary calcium excretion (relative hypocalciuria). It belongs to the family of familial hypocalciuric hypercalcemia (FHH) syndromes, which together are caused by defects in the CaSR signaling axis.

Key identifiers.

Synonyms / alternative names: Familial hypocalciuric hypercalcemia type 2; FHH2; Hypocalciuric hypercalcemia, familial, type II; Familial benign hypercalcemia type 2; GNA11-related FHH.

Source of information. The knowledge in this report is derived overwhelmingly from aggregated disease-level resources (OMIM, ClinVar, published functional studies) and from individual case reports / small kindreds — appropriate given that only ~8 FHH2 families have been described. There is no large EHR-scale cohort specific to FHH2 (unlike FHH1, which has been studied at biobank scale).

Section 2 — Etiology

Primary cause — genetic (Finding F001). FHH2 is caused by heterozygous loss-of-function (inactivating) mutations in GNA11, which encodes Gα11, the G-protein that couples the CaSR to intracellular signaling. This is a purely genetic, monogenic Mendelian disorder; there are no established infectious or environmental causes.

"loss- and gain-of-function mutations of the GNA11 gene on chromosome 19p13.3, which encodes the G-protein α-11 (Gα11) subunit, lead to FHH type 2 and ADH type 2, respectively" — PMID: 27647839

"Type 1 is due to loss-of-function mutations of the calcium-sensing receptor, a guanine nucleotide-binding protein (G-protein)-coupled receptor that signals through the G-protein subunit α11 (Gα11)" — PMID: 23802516

Genetic risk factors. The causal variants are the GNA11 loss-of-function alleles themselves. Because inheritance is autosomal dominant with high penetrance, carrying a single pathogenic allele is effectively the disease-defining risk factor. No separate susceptibility loci or modifier genes have been robustly established for FHH2 (small sample sizes preclude modifier mapping).

Environmental risk factors. None established. Family history (a first-degree relative with mild hypercalcemia or an unsuccessful parathyroidectomy) is the key non-laboratory clue. Age and sex do not materially alter risk; the trait is present from birth.

Protective factors. No genetic or environmental protective factors are documented. Because FHH2 is benign, "protection" is less relevant than for complication-prone disorders.

Gene–environment interactions. The most clinically important interaction is physiological/pharmacological rather than classic GxE: concurrent exposure to calcium-mobilizing drugs (e.g., antiresorptive regimens) can unmask or exaggerate hypercalcemia (one patient on alternating denosumab/zoledronic acid for osteonecrosis was subsequently diagnosed with FHH; PMID: 42822749). Pregnancy is another state that interacts with the genotype (see Section 8).

Section 3 — Phenotypes

FHH2 is typically an asymptomatic laboratory diagnosis (Finding F005). Core phenotypes are biochemical.

Characteristics. Onset is effectively congenital/lifelong but usually detected incidentally in adulthood on routine biochemistry. Severity is mild, and progression is stable (non-progressive). In reported FHH2 kindreds there is no nephrocalcinosis, no kidney stones, and normal bone mineral density on DXA (PMID: 42787214, PMID: 38920275, PMID: 42291983).

"He had no evidence of kidney stones or nephrocalcinosis and demonstrated normal bone mineral density at dual-energy X-ray absorptiometry." — PMID: 42787214

Newly recognized manifestation — enamel hypomineralization (Finding F005). A 2026 study reported 10 patients from 2 families in whom hypomineralized enamel co-segregated with hypercalcemia due to a GNA11 complete deletion or a frameshift truncation p.(Ser18Argfs*2) — the first link of abnormal enamel mineralization to a hypercalcemic condition.

"Abnormal enamel mineralization has been reported in genetic conditions associated with hypocalcemia but never with hypercalcemia." — PMID: 42670332

Quality of life. Because the disorder is usually asymptomatic and non-progressive, quality-of-life impact is minimal in the majority. The principal QoL risk is iatrogenic — unnecessary parathyroid surgery following misdiagnosis as PHPT. A minority with higher calcium (>1 mg/dL above ULN) may experience fatigue, polyuria/polydipsia and warrant treatment (PMID: 42291983).

Section 4 — Genetic / Molecular Information

Causal gene. GNA11 (G protein subunit alpha 11), chromosome 19p13.3, encoding Gα11; disorder OMIM #145981.

Pathogenic variants (Findings F002, F006). FHH2 variants are predominantly missense loss-of-function changes, with in-frame deletions, frameshift truncations, and whole-gene deletion also reported. Recurrent and representative FHH2-associated variants include:

A 10-year cohort of >1,200 probands tested for calcium disorders identified 37 germline GNA11 variants, of which 9 nonsynonymous changes (Thr54Met, Arg60His, Arg60Leu, Gly66Ser, Arg149His, Arg181Gln, Phe220Ser, Val340Met, Phe341Leu) were reported as FHH2- or ADH2-causing (PMID: 36970776).

Variant classification. Reported disease-causing variants are classified pathogenic/likely pathogenic by ACMG/AMP criteria, supported by co-segregation and in vitro functional assays (see below). Many additional rare GNA11 missense changes remain VUS pending functional data.

Allele frequency. Pathogenic FHH2 alleles are extremely rare in population databases (gnomAD), consistent with the ~8 known kindreds; no common susceptibility allele exists.

Somatic vs germline origin. FHH2-causing variants are germline. In contrast, somatic activating GNA11 mutations occur in uveal melanoma (distinct disease arm; see Section 6 / Finding F006).

Functional consequences (Finding F002). FHH2 variants are loss-of-function, reducing CaSR-mediated intracellular calcium signaling. In HEK293 cells expressing CaSR, FHH2 Gα11 variants (Thr54Met, Thr347Ala, Leu135Gln, Ile200del) downregulate IP1 accumulation and intracellular Ca²⁺ responses, producing a rightward shift (higher EC50 / reduced agonist potency) in the calcium concentration–response curve.

"loss-of-function variants in GNA11 lead to reduced agonist potency at CaSR and an FHH phenotype" — PMID: 38920275

"Three-dimensional modeling revealed the Thr54Met mutation to be located at the interface between the Gα11 helical and GTPase domains, and to likely impair GDP binding" — PMID: 26729423

Modifier genes / epigenetics / chromosomal abnormalities. No validated modifier genes or epigenetic mechanisms are established for FHH2. The only reported structural lesion is a complete GNA11 deletion (haploinsufficiency) associated with the enamel phenotype (PMID: 42670332).

Section 5 — Environmental Information

FHH2 is a monogenic disorder with no established environmental, lifestyle, or infectious etiology. Non-genetic factors are relevant only insofar as they modify measured calcium:

• Drugs: antiresorptive therapy (denosumab/bisphosphonates), thiazides, lithium, and vitamin D can perturb calcium and complicate interpretation; one FHH diagnosis emerged during antiresorptive therapy (PMID: 42822749).
• Lifestyle: no causal dietary or behavioral factor. Calcium/vitamin D intake does not cause the disease but may transiently affect levels.
• Infectious agents: none — not applicable.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. A heterozygous loss-of-function variant in GNA11 (e.g., Thr54Met) results in a Gα11 protein with impaired guanine-nucleotide handling / reduced coupling capacity (Thr54Met impairs GDP binding at the helical/GTPase interface). [Demonstrated in vitro and by structural modeling.]
2. Reduced functional Gα11 leads to weaker coupling of the plasma-membrane CaSR to its effector phospholipase C-β (PLCβ) in parathyroid chief cells (and renal tubular cells). [Demonstrated: reduced IP1/Ca²⁺ responses in CaSR+Gα11 HEK293 assays.]
3. Diminished CaSR→Gα11→PLCβ signaling results in a rightward shift (higher EC50) of the calcium concentration–response curve — the receptor now requires a higher extracellular calcium to achieve the same intracellular signal. [Demonstrated.]
4. This raises the calcium "set-point": at a normal serum calcium, the cell senses "too little calcium." [Inferred from set-point model, consistent with CaSR biology.]
5. In parathyroid chief cells, inadequate CaSR signaling fails to suppress PTH secretion, so PTH remains inappropriately normal/high-normal for the prevailing calcium. [Demonstrated clinically and in mouse model.]
6. In the kidney (distal tubule / thick ascending limb), blunted CaSR signaling leads to continued tubular calcium reabsorption, producing relative hypocalciuria (low CCCR). [Inferred from CaSR renal physiology; consistent with clinical phenotype.]
7. Steps 5 and 6 together result in sustained mild hypercalcemia with hypocalciuria and non-suppressed PTH — the defining FHH2 triad. [Demonstrated clinically.]

Branch A (reciprocal, same gene): A gain-of-function GNA11 variant instead lowers the set-point → excessive CaSR signaling → suppressed PTH and renal calcium wasting → ADH2 (hypocalcemia).

Branch B (somatic/oncogenic): Somatic activating GNA11 mutations in melanocytes constitutively upregulate MAPK signaling → uveal melanoma.

Supporting detail

Molecular pathways (Finding F007). CaSR is a family-C GPCR on the plasma membrane of parathyroid chief cells, also functionally expressed in kidney, bone and gut. It couples via Gq/G11 → PLCβ, generating IP3/DAG and raising intracellular Ca²⁺; it also engages AKT and MAPK. PI-PLC β1/β2/β3/β4 isozymes are expressed in parathyroid chief cells and are candidate CaSR effectors (PMID: 9723859).

"On the cell membrane of the chief cells of the parathyroid glands, the CaR 'senses' the extracellular calcium concentration and, subsequently, alters the release of parathyroid hormone (PTH)." — PMID: 15697170

"Functionally significant mutations in the receptor have been shown to induce diseases of calcium homeostasis owing to changes in the set point for calcium-regulated PTH release as well as alterations in the renal handling of calcium." — PMID: 15697170

Protein dysfunction. FHH2 is a loss-of-function of a signal-transducing G-protein α subunit — a defect in signal relay, not receptor or hormone structure. Structural modeling localizes the recurrent Thr54Met to the helical/GTPase domain interface, impairing GDP binding (PMID: 26729423).

Biochemical abnormality. The core defect is receptor–effector uncoupling causing set-point elevation — an ion-sensing/second-messenger signaling defect rather than an enzyme deficiency.

Allelic series (Finding F006).

"Familial hypocalciuric hypercalcemia type 2 (FHH2) and autosomal dominant hypocalcemia type 2 (ADH2) are due to loss- and gain-of-function mutations, respectively, of the GNA11 gene that encodes the G protein subunit Gα11, a signaling partner of the calcium-sensing receptor (CaSR)." — PMID: 36970776

"somatic Gα11 mutations mediate uveal melanoma development by constitutively up-regulating MAPK signaling" — PMID: 26994139

Suggested ontology terms. Biological processes: GO:0007200 (phospholipase C-activating GPCR signaling), GO:0055074 (calcium ion homeostasis), GO:0035556 (intracellular signal transduction). Cellular component: GO:0005886 (plasma membrane), GO:0005834 (heterotrimeric G-protein complex). Cell types: CL:0000446 (parathyroid chief cell); renal tubular epithelial cells. Chemical: CHEBI:29108 (calcium(2+) ion).

 GNA11 LOF variant
|
v
 Gα11 impaired (↓ GDP binding / coupling)
|
v
 CaSR -X-> PLCβ   (weak coupling; higher EC50)
|
v
 ↑ calcium set-point  ("senses low Ca at normal Ca")
|
   -------------------------------
   |                             |
 Parathyroid chief cell        Renal tubule
 PTH NOT suppressed            Ca reabsorption continues
   |                             |
   v                             v
 inappropriate normal/high     relative HYPOCALCIURIA
 PTH                            (low CCCR)
   \___________________________/
        |
        v
     MILD HYPERCALCEMIA (benign, lifelong)

Section 7 — Anatomical Structures Affected

Organ level. - Primary: Parathyroid glands (UBERON:0001132) — chief cells; Kidney (UBERON:0002113) — renal tubule. - Body system: Endocrine system (calcium/mineral homeostasis); urinary system (renal calcium handling). - Newly implicated: Teeth / dental enamel (UBERON:0001752 enamel) in the enamel-hypomineralization kindreds. - Secondary involvement: Minimal. Unlike PHPT, FHH2 kindreds show no nephrocalcinosis/stones and normal BMD, so bone and renal parenchyma are largely spared.

Tissue / cell level. - Parathyroid chief cells (CL:0000446) — epithelial endocrine cells. - Renal tubular epithelial cells (thick ascending limb / distal tubule).

Subcellular level. Plasma membrane (GO:0005886), where CaSR and the heterotrimeric Gq/G11 complex reside; downstream cytosolic second-messenger machinery (PLCβ, IP3/DAG).

Localization / lateralization. Systemic (all parathyroid glands and both kidneys); bilateral/symmetric by nature of a germline signaling defect.

Section 8 — Temporal Development

Onset. Genetically congenital (present from birth); clinically detected incidentally, usually in adulthood, on routine biochemistry. Onset pattern is chronic/insidious.

Progression. Stable and non-progressive — lifelong mild hypercalcemia without worsening. There are no defined "stages." Disease duration is chronic/lifelong.

Patterns. No spontaneous remission (it is constitutive). The only clinically relevant critical period is the perinatal window (see below) and any time point at which misdiagnosis could trigger unnecessary surgery.

Pregnancy / neonatal considerations (Finding F008). FHH (including FHH2) is one of the main PTH-dependent causes of gestational hypercalcemia alongside PHPT. Although maternal FHH is itself benign, maternal hypercalcemia transmitted to a non-carrier fetus can suppress the fetal parathyroids and cause transient neonatal hypocalcemia/tetany; conversely a neonate who inherits the inactivating variant may show transient neonatal hyperparathyroidism/hypercalcemia.

"PTH-dependent etiologies display increased or inappropriately high PTH levels; primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcemia (FHH) are the main contributors." — PMID: 42707509

"Severe cases of neonatal hypocalcemia due to fetal hypoparathyroidism may lead to tetany and even death." — PMID: 42707509

Management in pregnancy is largely conservative (hydration; cinacalcet crosses the placenta and is generally avoided) with postpartum and neonatal surveillance (PMID: 36546344, PMID: 27957351).

Section 9 — Inheritance and Population

Epidemiology (Finding F004). FHH as a whole is rare, with a classic prevalence estimate of ≥1 in 78,000 (West of Scotland); other sources cite ~1:80,000. FHH2 is the rarest subtype (FHH1 ~65% of FHH; FHH3 and FHH2 much less common), with only ~8 reported kindreds worldwide. Precise FHH2-specific incidence/prevalence figures are not established due to rarity and under-ascertainment.

"We estimate the prevalence to be 1 in 78,000 at least." — PMID: 11353947

Inheritance pattern. Autosomal dominant, high penetrance. A homozygous case (p.Tyr101His) has been reported with heterozygous, presumably milder, parents (PMID: 41240382).

Penetrance / expressivity. Penetrance of the biochemical trait is high (near-complete); expressivity is variable (degree of hypercalcemia, presence or absence of mild symptoms, the newly described enamel phenotype).

Anticipation / mosaicism / founder effects / consanguinity. No genetic anticipation (not a repeat-expansion disorder). No established germline mosaicism or founder effects specific to FHH2. Consanguinity is relevant for the rare homozygous presentation.

Carrier frequency. Not applicable in the recessive sense (dominant disorder); pathogenic alleles are vanishingly rare in gnomAD.

Population demographics. No ethnic predilection established; reported kindreds span multiple populations (e.g., an Italian kindred, PMID: 42787214). Sex ratio ~1:1 (autosomal). Age distribution: present lifelong, diagnosed across adulthood.

Section 10 — Diagnostics

Clinical/laboratory tests (Finding F004). The diagnostic signature is: - Serum calcium — mildly elevated (often <1 mg/dL above ULN); - PTH — inappropriately normal or mildly elevated (non-suppressed); - 24-h urinary calcium / CCCR — low; CCCR ≤0.01 is highly suggestive of FHH, whereas 0.01–0.02 is equivocal and warrants genetic testing; - Serum phosphorus — low/normal; magnesium — often high-normal.

"a calcium clearance to creatinine clearance ratio (Ca urine 24 h. x serum Cr) / (Cr urine 24 h x serum Ca) ≤ 0.01 is highly suggestive of the diagnosis of FHH" — PMID: 40198177

Reported FHH2 cases show CCCR/fractional calcium excretion well below 0.01 (e.g., FECa 0.0039; PMID: 42291983).

Imaging. Parathyroid imaging (ultrasound, sestamibi) is typically negative (no adenoma) and helps argue against PHPT; renal imaging shows no nephrocalcinosis/stones; DXA shows normal BMD.

Genetic testing. Definitive diagnosis is by sequencing GNA11, usually via a familial hypercalcemia / hyperparathyroidism gene panel (minimally CASR, GNA11, AP2S1, plus syndromic genes). Whole-exome sequencing (WES) has identified FHH2 variants in several reports (PMID: 42291983). Single-gene GNA11 testing is appropriate when the biochemical phenotype strongly suggests FHH but CASR/AP2S1 are negative. Cascade testing of relatives follows a confirmed proband.

Clinical criteria / differential diagnosis. The pivotal differential is primary hyperparathyroidism (PHPT); distinguishing them prevents inappropriate parathyroidectomy. Other differentials: the other FHH subtypes (FHH1 CASR, FHH3 AP2S1), acquired hypocalciuric hypercalcemia (AHH) due to anti-CaSR autoantibodies (PMID: 40335290), vitamin-D-metabolism disorders (CYP24A1, SLC34A1), and reduced GFR.

"Measurement of the urinary calcium-to-creatinine ratio clearance (UCCR) may help to distinguish patients with FHH from those with PHPT, as the majority of FHH patients have low urinary calcium excretion (UCCR < 0.01)." — PMID: 38038882

Genetic testing is especially advised in patients <30 years and those with equivocal CCCR (0.01–0.02) (PMID: 40683368).

Screening. Cascade genetic/biochemical screening of first-degree relatives once a proband variant is identified. No newborn screening exists for FHH2.

Section 11 — Outcome / Prognosis

Survival / mortality. FHH2 is benign with normal life expectancy; there is no disease-specific mortality. Unlike PHPT, it does not drive osteoporosis, nephrolithiasis, or renal failure in reported kindreds.

Morbidity / function. Minimal. The chief avoidable morbidity is iatrogenic — failed/unnecessary parathyroidectomy and its surgical risks when FHH is mistaken for PHPT (PMID: 38343604, PMID: 39818302).

Complications. Rare associations reported across FHH generally (e.g., chondrocalcinosis, pancreatitis) are more firmly linked to FHH1; a large genotype-first analysis of FHH1 did not confirm population-level excess pancreatitis/diabetes (PMID: 42640938). For FHH2 specifically, no consistent complication beyond mild hypercalcemia and the newly described enamel defect is established.

Prognostic factors. The main predictor of whether treatment is needed is degree of hypercalcemia (symptomatic or >1 mg/dL above ULN favors intervention). No molecular prognostic biomarkers are validated for FHH2.

Section 12 — Treatment

General principle. Most patients need no treatment — the priority is correct diagnosis to avoid unnecessary parathyroidectomy and reassurance/genetic counseling. Surgery is not indicated (hypercalcemia persists after parathyroidectomy because the defect is a systemic set-point shift, not an adenoma).

Pharmacotherapy — calcimimetics (Finding F003). For symptomatic or significant hypercalcemia, the calcimimetic cinacalcet (an allosteric CaSR activator; NCIT:C1876) is effective. It potentiates CaSR signaling, compensating for the weakened Gα11 relay.

"Cinacalcet (30mg/kg orally) significantly reduced plasma albumin-adjusted calcium and PTH concentrations in Gna11+/195G and Gna11195G/195G mice" — PMID: 29046478

"Cinacalcet and NPS-2143 rectified the Ca(2+) i responses of FHH2- and ADH2-associated Gα11 loss- and gain-of-function mutations, respectively" — PMID: 26994139

A human FHH2 patient (GNA11 p.Thr54Met) with calcium >1 mg/dL above ULN was treated with cinacalcet 30 mg daily; at three months serum calcium decreased and PTH normalized (PMID: 42291983). An earlier case also documented cinacalcet correcting FHH2 hypercalcemia (PMID: 28833550).

Pharmacogenomics. The therapeutic rationale is itself genotype-driven: the direction of the GNA11 variant dictates drug choice — calcimimetics (cinacalcet) for loss-of-function/FHH2; calcilytics (e.g., NPS-2143, investigational) for gain-of-function/ADH2.

Advanced / experimental therapeutics. No gene, cell, or RNA therapies exist or are needed for this benign disorder. No disease-specific clinical trials (NCT) are established for FHH2 beyond general calcimimetic use.

Surgical. Contraindicated/ineffective — parathyroidectomy does not cure FHH.

Supportive care. Hydration during intercurrent illness or pregnancy; avoidance of calcium-perturbing drugs; patient education and genetic counseling.

Treatment strategy. (1) Confirm diagnosis (biochemistry + CCCR + GNA11 genetics); (2) reassure and avoid surgery for the asymptomatic majority; (3) reserve cinacalcet for symptomatic/marked hypercalcemia; (4) manage pregnancy conservatively with neonatal surveillance.

Suggested NCIT terms: Cinacalcet (NCIT:C1876); Calcimimetic Agent; Parathyroidectomy (NCIT:C51764) — listed as not recommended.

Section 13 — Prevention

• Primary prevention: Not applicable — germline Mendelian disorder cannot be prevented. Preimplantation/prenatal genetic options could theoretically be discussed but are rarely pursued given the benign phenotype.
• Secondary prevention (early detection): Cascade genetic and biochemical screening of first-degree relatives after a proband is identified prevents misdiagnosis and inappropriate surgery.
• Tertiary prevention (complication avoidance): The central tertiary-prevention act is avoiding needless parathyroidectomy; perinatal surveillance to prevent/treat transient neonatal calcium disturbances.
• Genetic counseling: Autosomal dominant 50% transmission risk; counsel on benign prognosis, pregnancy/neonatal implications, and the value of family screening (PMID: 40757212).
• Immunization / public health / environmental: Not applicable.

Section 14 — Other Species / Natural Disease

• Taxonomy: Humans (Homo sapiens, NCBI:txid9606); experimentally modeled in mouse (Mus musculus, NCBI:txid10090).
• Orthologous gene: Gna11 in mouse (NCBI Gene ortholog of human GNA11).
• Natural disease in other species: No well-characterized naturally occurring GNA11-FHH2 equivalent is documented in companion animals or wildlife (OMIA does not list an established FHH2 animal counterpart). Not applicable/limited data.
• Comparative biology: The CaSR–Gα11 calcium-sensing axis is evolutionarily conserved across mammals, which is why the mouse model faithfully recapitulates the human phenotype (see Section 15).
• Transmission / zoonosis: Not applicable (non-infectious genetic disease).

Section 15 — Model Organisms

Mouse model (Finding F003). An ENU-generated Gna11 D195G mouse (loss-of-function) is the key disease model. It recapitulates FHH2 with hypercalcemia, normal/raised PTH, and normal urinary calcium. Both heterozygous (Gna11⁺/¹⁹⁵ᴳ) and homozygous (Gna11¹⁹⁵ᴳ/¹⁹⁵ᴳ) mice are hypercalcemic, and cinacalcet (30 mg/kg orally) significantly reduced plasma calcium and PTH, validating the model pharmacologically (PMID: 29046478).

Genetic model types available: point-mutant/knock-in mouse (above); cellular heterologous expression systems. Dedicated knockout, conditional, and humanized FHH2 lines are limited (reflecting rarity).

Phenotype recapitulation / limitations. The mouse captures the biochemical core (hypercalcemia, PTH, urine calcium) and drug response exceptionally well. Limitations: the newly described enamel phenotype and perinatal transient neonatal calcium dynamics are not yet modeled, and the model does not address human genotype–phenotype diversity across the ~8 kindreds.

Resources: MGI (Gna11), standard mouse repositories; HEK293/Cellosaurus for the in vitro system.

Mechanistic Model / Interpretation (Synthesis)

FHH2 is best understood as a set-point disorder of the CaSR–Gα11–PLCβ signaling module. The CaSR is the thermostat for serum calcium; Gα11 is the wire connecting that thermostat to the cell's effectors. A heterozygous loss-of-function GNA11 allele partially cuts the wire: the thermostat still "reads" calcium but transmits a weakened signal, so the body defends an abnormally high calcium level. Every clinical feature follows from this single lesion — non-suppressed PTH (parathyroid arm), relative hypocalciuria (renal arm), and mild, stable, lifelong hypercalcemia (the integrated output).

The elegance of the GNA11 allelic series reinforces the model: dialing signaling down gives hypercalcemia (FHH2); dialing it up germinally gives hypocalcemia (ADH2); dialing it up somatically in melanocytes gives uveal melanoma. The therapeutic logic is perfectly complementary — calcimimetics (cinacalcet) push signaling back up in FHH2, while calcilytics (NPS-2143) push it back down in ADH2, each rectifying the respective defect both in vitro and in vivo. This makes FHH2 a textbook example of mechanism-matched precision pharmacology, even though most patients require no treatment at all.

Evidence Base

Limitations and Knowledge Gaps

1. Extreme rarity. With only ~8 FHH2 kindreds reported, nearly all clinical evidence is from case reports and small series; there is no biobank-scale FHH2 cohort (in contrast to FHH1, now characterized at UK Biobank scale). Penetrance, expressivity, and complication rates are therefore imprecise.
2. Novel phenotype unconfirmed at scale. The enamel-hypomineralization association (PMID: 42670332) rests on 2 families and awaits independent replication and mechanistic explanation.
3. Renal arm inferred. The precise renal tubular contribution to hypocalciuria in FHH2 is inferred from CaSR physiology rather than directly demonstrated in FHH2 tissue.
4. Model gaps. The validated mouse captures biochemistry and drug response but not the enamel or perinatal phenotypes.
5. Modifiers unknown. No modifier genes, epigenetic mechanisms, or environmental contributors have been mappable given sample size.
6. Treatment evidence. Cinacalcet efficacy is supported but limited to a handful of patients and one mouse model; no randomized data exist specifically for FHH2.

Proposed Follow-up Experiments / Actions

1. Establish an international FHH2 registry pooling GNA11-confirmed kindreds to estimate penetrance, expressivity, complication frequency, and the true prevalence of the enamel phenotype.
2. Genotype-first biobank screening (UK Biobank, All of Us) for rare GNA11 LOF variants to define population prevalence and biochemical range, mirroring the FHH1 approach.
3. Functionally classify VUS: systematically run candidate GNA11 missense variants through the CaSR+Gα11 HEK293 IP1/Ca²⁺ assay to resolve ACMG classification and confirm LOF vs GOF direction.
4. Model the enamel phenotype: examine amelogenesis in Gna11-deficient mice and characterize CaSR/Gα11 signaling in ameloblasts to test whether enamel hypomineralization is a direct GNA11 effect.
5. Prospective cinacalcet evaluation in symptomatic FHH2 patients (small open-label/n-of-1 framework) with calcium, PTH, and urinary calcium endpoints.
6. Perinatal surveillance protocol: define evidence-based neonatal calcium monitoring for infants of FHH2 mothers, stratified by inferred fetal genotype.

Prepared from an autonomous 5-iteration investigation: 8 confirmed findings, 43 papers reviewed. Evidence types span human clinical case reports/kindreds, a validated mouse model, in vitro functional assays, and structural/computational modeling.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0007792 (2 mentions) - the report calls it "MONDO"; MONDO calls it familial hypocalciuric hypercalcemia 2
• HP:0003072 (1 mention) - the report calls it "Laboratory abnormality"; HP calls it Hypercalcemia
• HP:0012378 (1 mention) - the report calls it "Symptom"; HP calls it Fatigue

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0003165 (1 mention) - the report calls it "hyperparathyroidism"; HP calls it Elevated circulating parathyroid hormone level, and lists "Elevated serum parathyroid hormone" among its other names
• HP:0000682 (1 mention) - the report calls it "abnormality of dental enamel"; HP calls it Abnormal dental enamel morphology, and lists "Abnormality of dental enamel" among its other names
• GO:0007200 (1 mention) - the report calls it "phospholipase C-activating GPCR signaling"; GO calls it phospholipase C-activating G protein-coupled receptor signaling pathway, and lists "PLC-activating GPCR signaling pathway" among its other names
• CL:0000446 (2 mentions) - the report calls it "parathyroid chief cell", "chief cells", "Parathyroid chief cells"; CL calls it chief cell of parathyroid gland**, and lists "parathyroid chief cell" among its other names
• UBERON:0001132 (1 mention) - the report calls it "Primary: Parathyroid glands"; UBERON calls it parathyroid gland**

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• CL:0000446 - called "parathyroid chief cell", "chief cells", "Parathyroid **chief cells"